Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.
We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.
RESEARCH & DEVELOPMENT
September 28, 2023Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Events & Presentations
September 11, 2023 at 9:30 AM EDT
August 25, 2023 at 9:00 AM EDT
July 25, 2023 at 1:30 PM EDT